Diabetes mellitus has been treated orally with herbal remedies based on folk medicine since ancient times. Embelia ribes burm (Myrsinaceae), known commonly as vidanga, was used in Ayurveda for its anthelmintic activity. Ayurveda describes vidanga as pungent, causes increase in digestive fire, and cures flatulence and colic. A single study reported the antihyperglycemic activity of decoction of E. ribes in glucose-induced hyperglycemic albino rabbits. In the present study, the lipid-lowering and antioxidant potential of ethanolic extract of E. ribes burm was investigated in streptozotocin (40 mg/kg, IV, single injection)-induced diabetes in rats. Twenty days of orally feeding the extract (200 mg/kg) to diabetic rats resulted in significant ( P < 0.01) decrease in blood glucose, serum total cholesterol, and triglycerides, and increase in HDLcholesterol levels when compared to pathogenic diabetic rats. Further, the extract also lowered the liver and pancreas thiobarbituric acid-reactive substances (TBARSs) values ( P < 0.01) when compared to TBARS values of liver and pancreas of pathogenic diabetic rats. The results of test drug were comparable to gliclazide (25 mg/kg, orally), a standard antihyperglycemic agent. This is the first pilot study to provide biochemical evidence of potential of E. ribes in diabetic dyslipidemia. Keywords Diabetes; Dyslipidemia; Embelia ribes; Lipid Peroxidation; StreptozotocinAccording to the Framingham Heart Study [1], dyslipidemia, which can range from hypercholesterolemia to hyperlipoproteinemia, is one of the many modifiable risk factors for coronary artery disease (CAD), stroke, and peripheral vascular disease. In diabetic dyslipidemia, lipid abnormalities may be the result of unbalanced metabolic states of diabetes (i.e., hyperglycemia and insulin resistance).